A service review of fibroscan at King’s College Hospital, opportunities for service improvement in non-hepatology specialities

ABSTRACT

P54 Figure 1ConclusionUnsurprisingly, there were 1.5 times more fibroscan cases in the pre-covid year (1633 in 2019 compared to 1058 in 2021), indicating the negative impact of COVID-19 in the diagnosis of chronic liver diseases. In addition, NAFLD had a higher rate of advanced fibrosis compared to hepatitis B with the possibility of more sequential HBV follow-up, late referral of NAFLD or impact of fasting state on steatohepatitis.We need to evaluate the interval and indications of repeat fibroscan in each etiology due to no significant variation of LSM value despite different fibroscan intervals. We also need to improve the fibroscan access in district hospitals and other specialities regarding external referral data.